Compare Amphastar Pharmaceuticals Inc (AMPH) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs iShares MSCI India ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.3 (market cap $826.08M), while iShares MSCI India ETF trades at $49.05. The key difference: iShares MSCI India ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | INDA | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $30.81 | $55.29 |
52-Week Low | $16.87 | $45.42 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
INDA, the iShares MSCI India ETF, trades at $49.30 with a slight 0.57% daily gain amid a predominantly bearish technical outlook. The ETF faces mixed sentiment with India's strong 7.8% GDP growth (CNBC, 2026-06-05) contrasting with sectoral challenges in IT and clean energy. Technical indicators show neutral oscillators but bearish moving averages, with all support and resistance levels clustered around $49.
The outlook remains cautious due to macroeconomic risks from Middle East conflicts and domestic sector pressures. However, India's position as the fastest-growing large economy and analyst price targets suggesting upside potential (Seeking Alpha, 2026-06-03) offer long-term opportunities amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
